Moleculine

Semax Dosage Claims and Why This Peptide Travels by the Nose

Semax is a nasal drug in Russian practice. See why the brain barrier shaped that route, what duration data exist and why no injected dose is established.

Zone 2 6 min readOpened 23 Oct 2026Last reviewed 23 Oct 2026

Stop 5 of 7 on the Mind Line.

Cover illustration for Semax Dosage Claims and Why This Peptide Travels by the Nose

Searches for semax dosage assume a settled answer, yet the first thing to learn about this peptide is the road it travels, not an amount. Semax is a seven amino acid peptide developed in Russia, and in Russian practice it is a nasal drug, a choice that makes sense once you see the barrier around the brain. This stop explains that choice, tests the claims about how long it lasts against measured data, and states plainly that no established dose exists for unapproved human use. Read the Barrier at the Door stop first.

Why Semax Is Given Through the Nose

Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It combines a short fragment of the stress hormone ACTH with a Pro-Gly-Pro tail meant to slow breakdown. The blood-brain barrier, described in the Barrier at the Door stop, keeps most circulating peptides out of the brain, and enzymes in blood chew them up before they arrive. A nasal spray avoids both problems on paper, because the nose is thought to connect to the brain along olfactory and trigeminal nerve pathways, so a peptide dropped there might reach brain tissue without crossing the blood vessel wall. Peptide medicines that must work in the brain face this problem again and again, which is why so many are sprays and not injections, and why a needle gives no obvious advantage here.

Russian clinicians use that logic for stroke recovery. A 2024 review by Spirin and colleagues argues that the nasal route suits regulatory peptides when blocked vessels prevent a drug from reaching damaged tissue. It reports clinical benefit in acute and recovery stages of ischemic stroke, mostly from Russian studies. Those studies were often small, open or poorly controlled by modern standards, and they cannot be read as proof that a peptide spray works for every brain condition. A 2026 engineering review adds a caution: the field often treats any brain exposure as meaningful delivery, but reaching the nasal lining and reaching the target cells are different steps. For a peptide this small, the path is plausible, not proven, and the human data on how much arrives are very limited.

How Long Does Semax Last

Social posts answer how long does semax last with confident hours or days. The measured record is far narrower. In a brain membrane experiment, the peptide survived longer than an hour before enzymes cut it to smaller fragments. In human imaging work, healthy volunteers had scans before and then 5 and 20 minutes after a nasal dose, and the volume of one frontal brain network was larger than in the placebo group. Nothing in those studies tracks effect past minutes. The membrane test used rat tissue in a dish, so it says how fast an enzyme acts on the peptide there, not how long anything lasts in a living person. A scan showing a network change 20 minutes later is a timestamp, not a duration, and a single brain scan cannot say when an effect ends.

A stroke study measured blood BDNF in patients after courses of the drug and tied higher levels to better recovery scores, but it compared patients with and without the drug during rehabilitation. It cannot say how long a single exposure acts. The honest summary is that peptide levels in human blood and brain have not been charted well, and duration claims come from sellers, not from pharmacokinetic data. Short peptides are usually cleared quickly, as the Gut line shows for natural hormones, so a long lasting effect would need another explanation, such as changed gene activity, which remains a hypothesis.

Semax Dosage and Injection Questions

Terms such as semax peptide dosage, semax dosing, semax injection, semax subq dosage and semax injection dosage ask how to turn a nasal drug into a needle. I found no published human study of subcutaneous Semax, and no regulator has set an injected amount. One 2020 imaging abstract in 52 volunteers uses the word injection but does not state the route, so I could not confirm a needle was used. No amount is given here, and none is established. Amounts in animal papers are tied to the animal, and Russian clinical reports describe courses of a nasal product, not a transferable recipe.

QuestionWhat is documentedGap
Nasal use in RussiaClinical papers in stroke recoveryNo Western approval, mostly small trials
Semax injectionNo published human study foundNo route data, no amount
Duration of effectMinutes of imaging, hours in a membrane testNo human kinetics
Vendor chartsNumbers without a sourceCannot be checked

Without a trial, a published amount is just a number someone copied. A nasal product made by a licensed manufacturer has a known strength and a quality check, while a vial of unknown content has neither. Moving that vial into a needle also removes the one design feature the Russian drug was built around, the nasal route, and adds the risks of injection, such as infection and wrong volume. Nothing in the record suggests injection is safer, stronger or longer lasting, and anyone who says so is guessing. If you are curious about the drug, ask a clinician about the evidence, because they can read the original trials and tell you what they do and do not show.

Semax and Selank Dosage Pairings and Safety

The phrase semax and selank dosage appears because the two Russian peptides are marketed together. The same imaging team compared both against placebo in healthy volunteers and found distinct changes in links between the amygdala and the right temporal cortex. That is a brain scan finding in one session, not evidence for a combined course, and I found no trial that tests the pair as a regimen. Each peptide has its own sequence, history and weak spots in the record, so a rule drawn from one cannot be moved to the other, and a stack of two unproven products multiplies the unknowns instead of reducing them. Selank is covered in its own stop on the Mind line.

Regulation points the same way. The FDA lists Semax among substances nominated for compounding that were later withdrawn, noting it has no, or limited, safety information for the proposed routes of administration. In July 2026 an FDA advisory panel narrowly recommended adding Semax to the 503A bulks list, but the vote is non binding and agency staff opposed it. Quality stays the central risk for anyone outside a trial: a vial without lab traceability cannot be trusted, and the Bench stops explain how purity numbers are read. Without that traceability, even a correct label says little about what a vial really contains.

Conclusion

The honest answer on semax dosage is that no established dose exists for unapproved human use, and nothing published supports an injected schedule. The Russian record centres on a nasal product and on stroke recovery, with duration claims that run far ahead of measured data. Until independent trials report, treat any semax dosage chart as someone else's guess.

Sources

  1. PubMed, PMID 15344653
  2. PubMed, PMID 39166935
  3. PubMed, PMID 42820785
  4. PubMed, PMID 30225715
  5. PubMed, PMID 29798983
  6. PubMed, PMID 32342318
  7. U.S. FDA: Certain bulk drug substances use compounding may present significant safety risks

End of this stop

Done reading? Mark it, and the map, the line strips and the planner will tick it off.

Education only, not medical advice. No personal dosing advice and no sellers. See the disclaimer.